Eurofins Scientific, global specialists in bio-analysis, has produced a new test to detect the presence of avian influenza H5N1 in raw products such as poultry meat and eggs. 


The test, which has been validated in a number of laboratories worldwide, uses reverse transcriptase combined with a multiplex PCR where sequences specific to the virus can be detected.


The new test has been developed in response to continuing concern among producers and consumers that bird flu represents a serious threat to public health, despite the reassurances of the European Food Safety Authority (EFSA).


In October 2005, the EFSA said “whilst it is unlikely that H5N1 could be passed onto humans by raw meat or eggs, cooking food properly would inactivate the virus.”


Eurofins supports the conclusion of the EFSA, but feel that the new test will offer peace-of-mind to their customers. “We were very reluctant to introduce this assay as we concur with the EFSA scientists’ view that the risk is extremely low,” says Dr Bert Popping, Eurofins Director of Molecular Biology and Immunology. “But our clients from different industries demand zero risk for their employees and customers.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While Eurofins admits that there ‘zero risk’ is an unachievable goal, the company suggests that the new test significantly reduces any potential risk of infection.